$3.25 Billion is the total value of Redmile Group, LLC's 83 reported holdings in Q3 2018. The portfolio turnover from Q2 2018 to Q3 2018 was 43.9% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ARRY | Sell | ARRAY BIOPHARMA INC | $241,782,000 | -9.8% | 15,906,680 | -0.4% | 7.44% | -18.3% |
| XNCR | Sell | XENCOR INC | $118,085,000 | +1.4% | 3,030,143 | -3.7% | 3.63% | -8.2% |
| IMGN | Sell | IMMUNOGEN INC | $116,567,000 | -2.7% | 12,309,035 | -0.1% | 3.59% | -11.9% |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $101,588,000 | -38.1% | 8,402,617 | -20.1% | 3.12% | -44.0% |
| LIVN | Sell | LIVANOVA PLC | $74,294,000 | +24.1% | 599,288 | -0.1% | 2.29% | +12.4% |
| IFRX | Sell | INFLARX NV | $69,495,000 | +6.3% | 2,024,900 | -0.1% | 2.14% | -3.7% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS IN | $57,173,000 | -1.6% | 1,476,580 | -0.0% | 1.76% | -10.9% |
| ICUI | Sell | ICU MED INC | $51,453,000 | -4.9% | 181,972 | -1.2% | 1.58% | -13.8% |
| WCG | Sell | WELLCARE HEALTH PLANS INC | $49,967,000 | -42.8% | 155,909 | -56.1% | 1.54% | -48.2% |
| XERS | Sell | XERIS PHARMACEUTICALS INC | $42,414,000 | -7.4% | 2,412,640 | -0.0% | 1.30% | -16.1% |
| BLUE | Sell | BLUEBIRD BIO INC | $36,807,000 | -12.7% | 252,100 | -6.1% | 1.13% | -20.9% |
| CNC | Sell | CENTENE CORP DEL | $32,104,000 | -48.7% | 221,745 | -56.3% | 0.99% | -53.5% |
| MOR | Sell | MORPHOSYS AGsponsored ads | $24,027,000 | -37.6% | 899,900 | -29.1% | 0.74% | -43.5% |
| SYNH | Sell | SYNEOS HEALTH INCcl a | $22,088,000 | -52.0% | 428,473 | -56.4% | 0.68% | -56.5% |
| TCDA | Sell | TRICIDA INC | $15,122,000 | +1.2% | 495,000 | -1.0% | 0.46% | -8.5% |
| ODT | Sell | ODONATE THERAPEUTICS INC | $11,749,000 | -12.9% | 605,300 | -0.9% | 0.36% | -21.2% |
| NVTA | Sell | INVITAE CORP | $8,790,000 | +47.2% | 525,375 | -35.3% | 0.27% | +33.0% |
| STIM | Sell | NEURONETICS INC | $5,803,000 | -27.3% | 180,999 | -39.7% | 0.18% | -33.9% |
| JNCE | Sell | JOUNCE THERAPEUTICS INC | $2,765,000 | -70.3% | 425,415 | -65.0% | 0.08% | -73.1% |
| ELGX | Sell | ENDOLOGIX INC | $1,548,000 | -93.7% | 810,461 | -81.3% | 0.05% | -94.2% |
| VCEL | Sell | VERICEL CORP | $283,000 | -83.9% | 20,000 | -88.9% | 0.01% | -85.0% |
| SENS | Sell | SENSEONICS HLDGS INC | $214,000 | -96.0% | 44,900 | -96.6% | 0.01% | -96.2% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $164,000 | -92.3% | 11,320 | -89.4% | 0.01% | -93.1% |
| ARAY | Exit | ACCURAY INC | $0 | – | -29,000 | -100.0% | -0.00% | – |
| VRAY | Exit | VIEWRAY INC | $0 | – | -24,330 | -100.0% | -0.01% | – |
| VRX | Exit | VALEANT PHARMACEUTICALS INTL | $0 | – | -8,930 | -100.0% | -0.01% | – |
| NVRO | Exit | NEVRO CORP | $0 | – | -3,400 | -100.0% | -0.01% | – |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -25,800 | -100.0% | -0.02% | – |
| LIFE | Exit | ATYR PHARMA INC | $0 | – | -1,884,992 | -100.0% | -0.06% | – |
| UBX | Exit | UNITY BIOTECHNOLOGY INC | $0 | – | -250,400 | -100.0% | -0.13% | – |
| SRPT | Exit | SAREPTA THERAPEUTICS INC | $0 | – | -31,100 | -100.0% | -0.14% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -262,400 | -100.0% | -0.20% | – |
| INSP | Exit | INSPIRE MED SYS INC | $0 | – | -200,000 | -100.0% | -0.24% | – |
| VTL | Exit | VITAL THERAPIES INC | $0 | – | -1,095,111 | -100.0% | -0.26% | – |
| NLNK | Exit | NEWLINK GENETICS CORP | $0 | – | -1,611,746 | -100.0% | -0.26% | – |
| TFX | Exit | TELEFLEX INC | $0 | – | -79,886 | -100.0% | -0.73% | – |
| ABT | Exit | ABBOTT LABS | $0 | – | -449,300 | -100.0% | -0.93% | – |
| IRTC | Exit | IRHYTHM TECHNOLOGIES INC | $0 | – | -401,303 | -100.0% | -1.11% | – |
| INSM | Exit | INSMED INC | $0 | – | -2,033,492 | -100.0% | -1.63% | – |
| LH | Exit | LABORATORY CORP AMER HLDGS | $0 | – | -288,400 | -100.0% | -1.76% | – |
| ALXN | Exit | ALEXION PHARMACEUTICALS INC | $0 | – | -489,300 | -100.0% | -2.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2019-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 43 | Q3 2023 | 10.1% |
| ATARA BIOTHERAPEUTICS INC | 36 | Q3 2023 | 6.4% |
| FATE THERAPEUTICS INC | 34 | Q3 2023 | 17.2% |
| INVITAE CORP | 32 | Q3 2023 | 2.7% |
| REGENXBIO INC | 28 | Q3 2023 | 3.8% |
| CLOVIS ONCOLOGY INC | 27 | Q1 2020 | 6.7% |
| IMMUNOGEN INC | 27 | Q3 2023 | 13.2% |
| CASTLIGHT HEALTH INC SAN FRAN COM STK | 27 | Q1 2021 | 2.5% |
| ARRAY BIOPHARMA INC | 26 | Q2 2019 | 12.6% |
| DECIPHERA PHARMACEUTICALS IN | 25 | Q3 2023 | 7.0% |
View Redmile Group, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Neoleukin Therapeutics, Inc. | July 27, 2023 | 2,912,228 | 6.6% |
| IGM Biosciences, Inc. | June 28, 2023 | 3,291,092 | 9.9% |
| MedAvail Holdings, Inc. | June 21, 2023 | 124,507,268 | 73.1% |
| Achilles Therapeutics plc | February 14, 2023 | 1,608,089 | 3.9% |
| Kymera Therapeutics, Inc. | February 14, 2023 | 2,673,837 | 4.9% |
| Old Ayala, IncSold out | February 08, 2023 | 0 | 0.0% |
| Zymeworks Inc. | August 08, 2022 | 5,758,241 | 9.9% |
| Science 37 Holdings, Inc. | June 15, 2022 | 19,808,234 | 17.1% |
| Allakos Inc. | February 14, 2022 | 2,077,875 | 3.8% |
| Aprea Therapeutics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
View Redmile Group, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-10 |
| 4 | 2024-04-01 |
| 4 | 2024-04-01 |
| 4 | 2024-03-25 |
| SC 13D/A | 2024-03-25 |
| 4 | 2024-03-19 |
| 4 | 2024-03-14 |
| 4 | 2024-03-13 |
| SC 13D/A | 2024-03-13 |
View Redmile Group, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.